Translational Lung Cancer Research

Scope & Guideline

Empowering global collaboration in lung cancer research.

Introduction

Welcome to the Translational Lung Cancer Research information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Translational Lung Cancer Research, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN2218-6751
PublisherAME PUBLISHING COMPANY
Support Open AccessNo
CountryHong Kong
TypeJournal
Convergefrom 2012 to 2024
AbbreviationTRANSL LUNG CANCER R / Transl. Lung Cancer Res.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressFLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA

Aims and Scopes

Translational Lung Cancer Research aims to advance the understanding and treatment of lung cancer through innovative research and clinical studies, focusing on a wide range of topics related to diagnosis, treatment, and patient management.
  1. Clinical Research and Trials:
    The journal publishes studies related to clinical trials assessing the efficacy and safety of various treatments for lung cancer, including chemotherapy, immunotherapy, and targeted therapies.
  2. Biomarkers and Genomics:
    Research on the identification and validation of biomarkers for early detection, prognostication, and treatment response in lung cancer, emphasizing genomic alterations and their implications.
  3. Radiology and Imaging:
    Papers that explore advancements in imaging techniques, including CT, PET, and radiomics, to enhance diagnostic accuracy and guide treatment decisions.
  4. Patient-Centered Care:
    Studies focusing on the quality of life, psychological impact, and socioeconomic factors affecting lung cancer patients, including screening programs and survivorship.
  5. Innovative Therapeutic Approaches:
    Research on novel therapies and combinatorial approaches, including immunotherapy and personalized medicine, aimed at overcoming resistance and improving patient outcomes.
  6. Surgical Techniques and Outcomes:
    Publications detailing advancements in surgical procedures, including minimally invasive techniques, their efficacy, and associated outcomes.
  7. Epidemiology and Risk Factors:
    Research addressing the epidemiological aspects of lung cancer, including risk factors, demographics, and trends in incidence and mortality.
The journal has identified several emerging themes that reflect current trends in lung cancer research, indicating a dynamic shift towards innovative methodologies and patient-centered approaches.
  1. Immunotherapy and Combination Therapies:
    There is a significant increase in research focusing on immunotherapy, particularly combination therapies that integrate immune checkpoint inhibitors with other treatments to enhance efficacy.
  2. Liquid Biopsy and Circulating Biomarkers:
    Studies on liquid biopsy techniques and circulating tumor DNA (ctDNA) are gaining momentum, offering non-invasive methods for monitoring treatment responses and disease progression.
  3. Artificial Intelligence in Diagnostics:
    The integration of AI and machine learning in the analysis of imaging and genomic data is emerging as a powerful tool for improving diagnostic accuracy and personalizing treatment plans.
  4. Real-World Evidence Studies:
    An increasing number of publications are focusing on real-world data to evaluate treatment effectiveness and patient outcomes outside of controlled clinical trial settings.
  5. Health Disparities and Access to Care:
    Research addressing health disparities in lung cancer screening and treatment access is gaining traction, highlighting the need for equitable healthcare solutions.
  6. Microbiome Research:
    Exploration of the role of the microbiome in lung cancer development and treatment response is emerging as a novel area of investigation, linking systemic health with cancer outcomes.

Declining or Waning

While some areas of research continue to thrive, others have shown a decline in focus within the journal, reflecting shifts in the scientific landscape and clinical priorities.
  1. Traditional Chemotherapy Studies:
    As targeted therapies and immunotherapy gain prominence, traditional chemotherapy studies are becoming less frequent, indicating a shift towards more innovative treatment modalities.
  2. Basic Science and Preclinical Studies:
    There is a noticeable reduction in purely basic science studies that do not directly translate to clinical applications, as the journal increasingly prioritizes translational research.
  3. General Epidemiological Surveys:
    Research focusing on broad epidemiological surveys without specific interventions or novel insights is declining, as more targeted and actionable studies are favored.
  4. Non-Clinical Patient Experience Studies:
    Papers focusing on non-clinical aspects of patient experience, such as general quality of life without specific cancer-related interventions, are diminishing in frequency.

Similar Journals

Thoracic Cancer

Empowering research for a cancer-free tomorrow.
Publisher: WILEYISSN: 1759-7706Frequency: 24 issues/year

Thoracic Cancer is a distinguished open-access journal published by WILEY, dedicated to advancing the field of thoracic oncology. Since its establishment in 2010, the journal has emerged as a crucial platform for the dissemination of innovative research and clinical studies relating to lung cancer and other thoracic malignancies. With a commendable impact reflected in its 2023 Q2 rankings in the categories of Medicine (Miscellaneous), Oncology, and Pulmonary and Respiratory Medicine, the journal features high-quality articles that are vital for researchers, clinicians, and students aspiring to enhance their understanding of thoracic cancers. Operating out of Australia, Thoracic Cancer has embraced a commitment to open access since 2015, ensuring that vital research is readily available to a global audience. The journal's rigorous peer-review process and emphasis on novel findings make it an indispensable resource for professionals seeking to stay at the forefront of this rapidly evolving field.

Cancers

Empowering discovery in oncology and cancer treatment.
Publisher: MDPIISSN: Frequency: 24 issues/year

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

Journal of Cancer

Unlocking the complexities of cancer together.
Publisher: IVYSPRING INT PUBLISSN: 1837-9664Frequency: 12 issues/year

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.

BRITISH JOURNAL OF CANCER

Pioneering Insights in Oncology Since 1947.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

Clinical Lung Cancer

Leading the way in comprehensive lung cancer exploration.
Publisher: CIG MEDIA GROUP, LPISSN: 1525-7304Frequency: 6 issues/year

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.

INTERNATIONAL JOURNAL OF CANCER

Shaping the future of oncology through rigorous research.
Publisher: WILEYISSN: 0020-7136Frequency: 24 issues/year

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

South Asian Journal of Cancer

Advancing cancer research in South Asia.
Publisher: GEORG THIEME VERLAG KGISSN: 2278-330XFrequency: 4 issues/year

South Asian Journal of Cancer, published by GEORG THIEME VERLAG KG, is a pivotal platform for research in the fields of oncology and cancer research. Established in 2012 and operating under an Open Access model, this journal aims to disseminate high-quality, peer-reviewed articles that address crucial developments in cancer treatment, prevention, and research, particularly within the South Asian context. Despite its young history, the journal has been positioned within the Q4 quartile for both Cancer Research and Oncology, and while current Scopus rankings indicate it resides in the lower percentiles, its commitment to amplifying regional voices and research is invaluable. With its headquarters in Stuttgart, Germany, and a global readership, South Asian Journal of Cancer is dedicated to enhancing collaboration among researchers, healthcare professionals, and students, fostering a space for innovative ideas and advancements in cancer care as we progress through to 2024.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Empowering Oncology Through Innovative Trials
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0277-3732Frequency: 12 issues/year

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of oncology and cancer research, focusing on the latest advancements in clinical trials and therapeutic strategies for cancer management. With an ISSN of 0277-3732 and an E-ISSN of 1537-453X, this journal serves as an essential resource for the dissemination of high-quality research findings, scholarly reviews, and innovative methodologies, aiming to advance clinical oncology from 1982 to 2024. It is categorized in Q3 for Cancer Research and Q2 for Oncology, reflecting its significant role in the scientific community. In addition to its rigorous peer-reviewed content, the journal provides a platform for researchers and clinicians to share valuable insights, laying the groundwork for future breakthroughs in cancer treatment. Although it currently does not offer open-access options, the journal remains accessible to a wide audience through academic institutions and libraries. The AMERICAN JOURNAL OF CLINICAL ONCOLOGY is crucial for anyone involved in oncology research, making it a must-read for professionals dedicated to improving cancer care.

Lung Cancer-Targets and Therapy

Elevating the Standards of Oncology Research
Publisher: DOVE MEDICAL PRESS LTDISSN: Frequency: 1 issue/year

Lung Cancer - Targets and Therapy, published by Dove Medical Press Ltd, serves as a pivotal Open Access journal dedicated to advancing knowledge and research in the field of oncology, specifically focusing on lung cancer. Since its inception in 2010, this journal has provided a platform for disseminating high-quality research articles, reviews, and clinical studies, thereby enhancing the understanding of lung cancer mechanisms, therapies, and clinical outcomes. Currently ranked in the Q2 quartile within the oncology category and positioned at rank #80 out of 404 in Scopus, it resides in the 80th percentile of its field, reflecting its significant impact and relevance. With a commitment to promoting innovative therapies and strategies, Lung Cancer - Targets and Therapy is an essential resource for researchers, healthcare professionals, and students eager to contribute to the evolving landscape of cancer treatment and research.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Pioneering Insights in Cancer Treatment and Research.
Publisher: SPRINGERISSN: 0171-5216Frequency: 12 issues/year

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.